NASDAQ:CNTX Context Therapeutics - CNTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.66 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.64▼$0.7050-Day Range$0.62▼$1.0652-Week Range$0.60▼$2.79Volume66,753 shsAverage Volume2.29 million shsMarket Capitalization$10.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Context Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside506.1% Upside$4.00 Price TargetShort InterestHealthy1.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 2 Articles This WeekInsider TradingAcquiring Shares$29,520 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.05) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector239th out of 983 stocksPharmaceutical Preparations Industry101st out of 478 stocks 3.5 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Context Therapeutics has a forecasted upside of 506.1% from its current price of $0.66.Amount of Analyst CoverageContext Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.13% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 27.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 3.0 News and Social Media Coverage News SentimentContext Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,520.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.66% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.88% of the stock of Context Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to decrease in the coming year, from ($1.05) to ($1.58) per share.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Context Therapeutics (NASDAQ:CNTX) StockContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesMarch 15, 2023 | proactiveinvestors.comContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meetingMarch 15, 2023 | finance.yahoo.comContext Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023March 22, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 13, 2023 | benzinga.comDiamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)February 13, 2023 | finance.yahoo.comUPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)February 7, 2023 | finance.yahoo.comContext Therapeutics announces positive responses in Phase 2 OATH clinical trialFebruary 6, 2023 | proactiveinvestors.comContext Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancerFebruary 6, 2023 | proactiveinvestors.comContext Therapeutics announces positive responses in Phase II OATH clinical trialMarch 22, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 6, 2023 | finance.yahoo.comContext Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerFebruary 2, 2023 | barrons.comContext Therapeutics Inc.January 31, 2023 | benzinga.comWhy Context Therapeutics (CNTX) Shares Are Seeing Blue SkiesJanuary 31, 2023 | proactiveinvestors.comContext Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancersJanuary 31, 2023 | msn.comContext stock soars ~70% as trial partner Stemline's breast cancer drug gets FDA approvalJanuary 31, 2023 | finance.yahoo.comContext Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerJanuary 25, 2023 | proactiveinvestors.comContext Therapeutics published in STAT Report on new cancer targetsJanuary 17, 2023 | proactiveinvestors.comContext Therapeutics releases CTIM-76 Claudin 6 Therapeutic Antibody updatesJanuary 9, 2023 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersJanuary 9, 2023 | proactiveinvestors.comContext Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancersJanuary 9, 2023 | finance.yahoo.comContext Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersJanuary 4, 2023 | proactiveinvestors.comContext Therapeutics has 39.4M cash runway to advance pipeline programs; data update from OATH Phase 2 trial likely in mid-2023January 4, 2023 | finance.yahoo.comContext Therapeutics® Highlights 2023 Corporate Priorities and Pipeline MilestonesDecember 12, 2022 | proactiveinvestors.comContext Therapeutics announces encouraging initial Ph 2 trial ONA-XR metastatic breast cancer dataDecember 8, 2022 | proactiveinvestors.comContext Therapeutics reports encouraging preliminary Phase 2 data for ONA-XR in metastatic breast cancerDecember 8, 2022 | finance.yahoo.comContext Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerDecember 8, 2022 | finance.yahoo.comContext Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerDecember 2, 2022 | proactiveinvestors.comContext Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Company Calendar Today3/21/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+506.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.40% Return on Assets-31.28% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book0.22Miscellaneous Outstanding Shares15,970,000Free Float14,903,000Market Cap$10.54 million OptionableNot Optionable Beta2.47 Key ExecutivesMr. Martin A. Lehr (Age 38)Co-Founder, Pres, CEO & Director Comp: $523.71kMs. Jennifer Minai-Azary (Age 44)CFO & Treasurer Comp: $404.33kMr. Alex C. Levit Esq. (Age 43)Chief Legal Officer & Corp. Sec. Comp: $490.82kDr. Felix Kim Ph.D.Co-founder & Chair of Scientific Advisory BoardMr. Christopher Beck M.B.A.Sr. VP of OperationsDr. Tarek Sahmoud M.D. (Age 61)Ph.D., Chief Medical Officer Dr. Evan G. Dick (Age 70)Sr. VP of R&D Ms. Elizabeth Nemchik CPAControllerMore ExecutivesKey CompetitorsEvoke PharmaNASDAQ:EVOKGraybug VisionNASDAQ:GRAYAlimera SciencesNASDAQ:ALIMHillstream BioPharmaNASDAQ:HILSSonnet BioTherapeuticsNASDAQ:SONNView All CompetitorsInsiders & InstitutionsMartin A LehrBought 5,823 shares on 2/21/2023Total: $4,891.32 ($0.84/share)AIGH Capital Management LLCSold 148,026 shares on 2/16/2023Ownership: 7.162%Virtu Financial LLCBought 57,455 shares on 2/15/2023Ownership: 0.360%swisspartners Ltd.Bought 95,000 shares on 2/14/2023Ownership: 1.127%Martin A LehrBought 5,606 shares on 2/13/2023Total: $4,877.22 ($0.87/share)View All Insider TransactionsView All Institutional Transactions CNTX Stock - Frequently Asked Questions Should I buy or sell Context Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTX shares. View CNTX analyst ratings or view top-rated stocks. What is Context Therapeutics' stock price forecast for 2023? 1 analysts have issued 12-month target prices for Context Therapeutics' shares. Their CNTX share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 506.1% from the stock's current price. View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts. How have CNTX shares performed in 2023? Context Therapeutics' stock was trading at $0.6517 at the start of the year. Since then, CNTX shares have increased by 1.3% and is now trading at $0.66. View the best growth stocks for 2023 here. Are investors shorting Context Therapeutics? Context Therapeutics saw a decline in short interest in February. As of February 28th, there was short interest totaling 152,900 shares, a decline of 27.2% from the February 13th total of 210,100 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the shares of the stock are sold short. View Context Therapeutics' Short Interest. When is Context Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our CNTX earnings forecast. When did Context Therapeutics IPO? (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share. What is Context Therapeutics' stock symbol? Context Therapeutics trades on the NASDAQ under the ticker symbol "CNTX." Who are Context Therapeutics' major shareholders? Context Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (7.16%), swisspartners Ltd. (1.13%), Renaissance Technologies LLC (0.66%) and Virtu Financial LLC (0.36%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Context Therapeutics' stock price today? One share of CNTX stock can currently be purchased for approximately $0.66. How much money does Context Therapeutics make? Context Therapeutics (NASDAQ:CNTX) has a market capitalization of $10.54 million. How can I contact Context Therapeutics? Context Therapeutics' mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The official website for the company is www.contexttherapeutics.com. The company can be reached via phone at 267-225-7416. This page (NASDAQ:CNTX) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.